Результаты поиска

Efficacy of a novel device for cryoprevention of oral mucositis: a randomized, blinded, multicenter, parallel group, phase 3 trial.

Cryoprevention (CP) using ice (IC) is an effective strategy to prevent chemotherapy-induced oral mucositis (OM). However, the use of IC may cause adverse reactions and requires water of safe quality to minimize risk of serious infections. This randomized, blinded, parallel group, phase 3 trial was conducted in five Scandinavian centers. Eligible patients were diagnosed with multiple myeloma or lymphoma, scheduled to receive conditioning with high-dose chemotherapy prior to autologous hematopoietic stem cell transplantation (ASCT). Patients were assigned to cooling with IC or a novel intraoral

Совпадение в полном тексте источника
… One explanation for this is that IC may entail adverse reactions such as chills, nausea, and shooting with sharp pain in the teeth, which could influence patient tolerability, leading to poorer adherence [ 2 , 17 , 18 ]. … Multiple myeloma and lymphoma | Ice chips (IC = 87) | Intraoral cooling device (ICD = 80) | p -Value Adverse events ( n ) [%] Chills | 24 [27.6%] | 13 [16.3%] | 0.078 Numbness | 9 [10.3%] | 2 [2.5%] | 0.041 Bad taste | 6 [6.9%] | 2 [2.5%] | 0.281 Headache | 2 [2.3%] | 2 [2.5%] | 1.000 Teeth hypersensitivity …

Second-Class Care: How Immigration Law Transforms Clinical Practice in the Safety Net.

This article examines how U.S. immigration law extends into the health care safety net, enacting medical legal violence that diminishes noncitizens' health chances and transforms clinical practices. Drawing on interviews with health care workers in three U.S. states from 2015 to 2020, I ask how federal citizenship-based exclusions within an already stratified health care system shape the clinical trajectories of noncitizens in safety-net institutions. Focusing specifically on cancer care, I find that increasingly anti-immigrant federal policies often reshape clinical practices toward noncitize

Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma.

BackgroundAccumulating pre-clinical data indicate that the efficient induction of antigen-specific cytotoxic CD8+ T cells characterizing viral infections is caused by cross-priming where initially infected DCs produce an unique set of inflammatory factors that recruit and activate non-infected bystander DCs. Our DC-based immunotherapy concept is guided by such bystander view and accordingly, we have developed a cellular adjuvant consisting of pre-activated allogeneic DCs producing high levels of DC-recruiting and DC-activating factors. This concept doesn't require MHC-compatibility between inj

Совпадение в полном тексте источника
… Safety In terms of AEs (Table 2 ), the probably or possibly drug-related events reported were fever (5 patients) and chills (2 patients) in connection with fever episodes. … Table 2 Treatment-related adverse events possibly or probably related to INTUVAX after first and second vaccination Reported Adverse event No of related AEs (no. of patients) CTCAE-grade (range) Fever 8 (5) 1–2 Chills 2 (2) 1 Rash 1 (1) 1 Hypotension 1 (1) 2 Table 2 Treatment-related adverse events …

Острая поздняя нейтропения у беременной пациентки с множественным склерозом после Оклелизумаба.

ВВЕДЕНИЕ: &lt; &lt; Окрелизумаб &gt; &gt; является рекомбинантом, очеловеченным anti-CD20 Моноклональная антитела лечила множественный склероз. Запоздалая нейтроплания, абсолютное число нейтрофильов <1.5 × 109/L, развивающийся >4 Неделю спустя после последней наркодирекции известное неблагоприятное событие, связанное с anti-CD20 моноклонные антитела, включая ritoximab и ocrelizumab. ПРЕДСТАВЛЕНИЕ СЛЕДУЮЩЕЙ СЛЕДУЮЩЕЙ ГРУППЫ: 27-year-old Женщина, разработавшая серьёзную нейтрализацию в течение третьего триместра беременности после лечения острелизумомb 6 Несколько месяцев назад.ЗАКЛЮЧЕНИЕ: Невро

Совпадение в полном тексте источника
… On hospital day 2, she developed chills, tender right submandibular lymphadenopathy, and severe mucositis. G-CSF was recommended. Prior to initiation of G-CSF, bone marrow biopsy showed hypocellular bone marrow with granulocytic maturation arrest and expanded monocytes. …

Review of Hematology-Oncology Emergencies for Internal Medicine Residents.

The prevalence of cancer continues to grow globally every year. With therapeutic advances over the recent decades, the prevalence of individuals living with cancer continues to increase. Internal medicine residents can see patients admitted to the hospital for cancer-related emergencies. Early identification and appropriate management of these emergencies have been shown to improve mortality and morbidity. In this article, we aim to review the recent updates in the management of commonly encountered oncologic emergencies in the practice of internal medicine residents. This review will cover sp

Совпадение в полном тексте источника
… Warning signs include tachycardia, hypotension, electrolyte abnormalities, fever, chills, leukocytosis, and lactic acidosis. Signs of peritonitis suggest microbial translocation into the abdominal cavity, bowel wall necrosis, and/or perforation ​[ 27 ]. … Organ-specific symptoms include mucocutaneous (pruritus, rash, desquamation, hives), respiratory (dyspnea, bronchospasm, and acute laryngopharyngeal dysesthesia usually caused by oxaliplatin), circulatory (hypo-or hypertension, shock), fever, and chills. …

Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study.

Smouldering multiple myeloma (SMM) is associated with increased risk of progression to multiple myeloma within 2 years, with no approved treatments. Elotuzumab has been shown to promote natural killer (NK) cell stimulation and antibody-dependent cellular cytotoxicity (ADCC) in vitro. CD56dim (CD56dim /CD16+ /CD3- /CD45+ ) NK cells represent the primary subset responsible for elotuzumab-induced ADCC. In this phase II, non-randomized study (NCT01441973), patients with SMM received elotuzumab 20 mg/kg intravenously (cycle 1: days 1, 8; monthly thereafter) or 10 mg/kg (cycles 1, 2: weekly; every 2

Совпадение в полном тексте источника
… ) | 15 (100) | 7 (47) | 16 (100) | 6 (38) Upper respiratory tract infection | 8 (53) | 1 (7) | 10 (63) | 0 Fatigue | 7 (47) | 0 | 6 (38) | 1 (6) Constipation | 4 (27) | 0 | 3 (19) | 0 Diarrhoea | 4 (27) | 0 | 3 (19) | 1 (6) Arthralgia | 4 (27) | 0 | 5 (31) | 0 Insomnia | 4 (27) | 0 | 6 (38) | 1 (6) Chills … Infusion reactions (IRs) were reported in 3 patients (20%) in the 20 mg/kg cohort and 1 patient (6%) in the 10 mg/kg cohort, and included palpitations, dyspepsia, chills and hypersensitivity (1 event each) in the 20 mg/kg cohort and pyrexia (1 event) in the 10 mg/kg cohort. …

Pseudomonas otitidis Bacteremia in a Patient with Cancer during the Palliative-care Phase.

Pseudomonas otitidis bacteremia is rare. We herein report a case of bacteremia caused by P. otitidis in a patient with advanced appendiceal cancer. A 79-year-old Japanese man developed infection when he was admitted to our hospital for palliative care. Blood culture revealed the presence of Pseudomonas spp. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry was used to identify the organism accurately. The patient was treated with a two-week course of piperacillin/tazobactam, and the bacteremia was successfully controlled. Clinicians should be aware that P. otitidis c

Совпадение в полном тексте источника
… On day 5, the patient developed a fever with chills, and ampicillin/sulbactam was initiated (3 g every 12 h) for a presumed upper respiratory infection. On day 7, two sets of blood cultures revealed the presence of Pseudomonas spp. An infectious disease consultation was also performed. …

Systematic review of patient-reported outcome item libraries in cancer research: an EORTC Quality of Life Group study.

BackgroundPatient-reported outcome (PRO) item libraries support flexible PRO assessment in cancer research by facilitating the development of customized item lists. However, little is known about the use of item lists in clinical research. This systematic review addresses this by assessing utilization of PRO item libraries and lists in oncology research.MethodsA systematic review of MEDLINE, Embase, and CINAHL identified cancer studies using PRO item libraries to develop item lists, regardless of study design, published between October 2021 and September 2025. Key features of item library usag

Совпадение в полном тексте источника
… ) | Lung | Immunotherapy | Symptomatic adverse event tracking; efficacy, effectiveness or clinical benefit | QLQ-C30; QLQ-LC13; Patient Global Impression of Severity and Change | FACIT; PRO-CTCAE | 17 | Arm or leg swelling (3); heart palpitations (2); headache (3); anxiety (3); shivering or shaking chills … (1); weakness (1); speaking (1); lack of energy (1); feeling of malaise (1); bone aches (1); coughing (1); changes in sexual functioning (1); inability to eat (1); irritability (1); muscle soreness or cramping (1); difficulty paying attention (1); headache (1); poor balance or falling (1); fever or chills …

Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy.

Chemotherapy-associated cardiotoxicity can present as a spectrum from arrhythmia to acute congestive heart failure. Unlike anthracyclines, proteasome inhibitors - for example, bortezomib - are not notorious for causing cardiotoxicity in absence of pre-existing cardiac dysfunction or without concomitant use of other cardiotoxic agents. We describe a 66-year-old woman with end-stage renal disease who developed acute dyspnea hours after a third treatment with bortezomib for IgG kappa myeloma. The Naranjo adverse drug reaction probability scale indicated a probable relationship (score of 5) betwee

Совпадение в полном тексте источника
… She had no fever, chills, cough, sputum production, orthopnea, pain, or change in bladder or bowel habits. …

Covalent targeting of PSMD14 by Eupalinolide B induces oncoprotein degradation and apoptosis in acute promyelocytic leukemia cells.

Treatment of acute promyelocytic leukemia (APL) remains challenged by toxicities associated with current regimens, highlighting the need for novel and safer therapeutic agents. Here, we identify Eupalinolide B (EB), a natural sesquiterpene lactone isolated from Eupatorium lindleyanum DC., as a potent anti-leukemic compound targeting the human APL-derived HL-60 cell line. Through integrated chemoproteomic profiling and functional validation, we demonstrate that EB covalently binds and inhibits 26S proteasome non-ATPase regulatory subunit 14 (PSMD14), a deubiquitinase enzyme (DUB) within the 19S

Antibiotic prophylaxis in percutaneous nephrostomy placements and replacements for malignant urinary tract obstruction. Retrospective cohort study with systematic review and meta-analysis.

INTRODUCTION: Percutaneous nephrostomy (PN) can lead to urinary tract infections (UTIs), but these can be prevented by administering antibiotics. However, the effectiveness of this approach is debated. METHODS: To evaluate the association between PN-related UTIs and antibiotic prophylaxis in cancer patients. This is a hybrid study was designed. A retrospective cohort study was conducted on cancer patients requiring PN, comparing antibiotic prophylaxis with no prophylaxis. The outcome, UTI, was measured up to seven days after the procedure. This cohort study was included in a systematic review

Совпадение в полном тексте источника
… Furthermore, while one study defines urinary sepsis as fever and chills ( 12 ), others use criteria such as urine culture results and the patient's clinical condition to define a PN catheter-related UTI ( 10 , 13 – 15 ). … Definitions and conduct of the study As there is no standard definition of PN-related UTIs in the literature, definitions were established for the purpose of conducting this study and evaluating the proposed topic: UTI occurs when there are signs and symptoms consistent with a local infection (fever, chills …

Nephrotoxicity in Bispecific Antibodies Recipients: Focus on T-Cell-Engaging Bispecific Antibodies.

Recently, bispecific antibodies (BsAbs) are evolving the landscape of cancer treatment and have significantly improved the outcomes of relapsed or refractory cancer patients. As increasing BsAbs entered clinical practice, specific toxicities have emerged, and renal side-effects have been described. However, there are a lack of studies analyzing the nephrotoxicity in the anti-cancer BsAbs recipients systematically. In this review, we demonstrate the etiologies, mechanisms, other risk factors and treatment options of kidney injury in the BsAbs recipients to provide a more comprehensive insight i

Совпадение в полном тексте источника
… headache (35.3%), nausea (29.4%), vomiting (29.4%), most of CRS are mild and transient | Systolic hypertension: 2/17 (11.8%) 3 | Catumaxomab | EpCAM x CD3 | Morten Mau-Sørensen | Phase I | Epithelial cancers with known EpCAM expression | Many have CRRS | Creatinine increased: 4/16 (25.0%) | CRRS including chills … Cytokine Release Syndrome CRS is a common complication of T-cell-engaging BsAbs treatment. 28–30 The most common symptoms of BsAbs-induced CRS are fever, chills, headache, dizziness, and fatigue. 30 The clinical features of this syndrome are associated with high levels of inflammatory markers and cytokines …

Navigating uncharted waters: assessing the impact of the COVID-19 pandemic on hematopoietic stem cell transplantation: challenges and innovations.

The COVID-19 pandemic has significantly impacted hematopoietic stem cell transplantation (HSCT), necessitating adaptations across pre-transplant, transplantation, and post-transplant phases. HSCT recipients with compromised immune systems face heightened risks of severe COVID-19 outcomes, including increased mortality. The pandemic prompted significant changes in treatment strategies, with many patients experiencing delays or deferrals in autologous stem cell transplantation (ASCT), alongside adjustments to chemotherapy regimens to prevent disease recurrence. Clinical practices have evolved to

Совпадение в полном тексте источника
… Aside from local reactions, patients also had systemic symptoms, such as asthenia in 20–41% of cases, myalgia and headache in 15–30% of cases, and chills in 7–15% of instances 42 . … antibody response rates) | HSCT: 81.4% after complete vaccination; 40.8% after 1 dose; 78.6% after 3rd dose - CAR-T: Combined serological response rate of 35.9% Noted side effects | Mild to moderate; predominantly local reactions (pain, redness, swelling), systemic symptoms (asthenia, myalgia, headache, chills …

Correlates of quality of life in South Korean patients undergoing hematopoietic stem cell transplantation based on the symptom management model.

While hematopoietic stem cell transplantation (HSCT) has led to higher survival rates, the number of patients experiencing adverse reactions is also increasing. Based on the symptom management model, we aimed to analyze the relationships between symptom experience, symptom management strategies, self-management behavior, and quality of life among patients undergoing HSCT in South Korea and to identify the factors affecting their quality of life. The data of 67 conveniently sampled patients undergoing HSCT at a university-affiliated hospital, for the period from March 23 to June 7, 2016, were c

Re-Cellularised Kidney Scaffold for Chikungunya Virus Propagation: A Novel Approach.

BACKGROUND: Re-emerging viral attacks are catastrophic for health and economy. It is crucial to grasp the viral life cycle, replication and mutation policies and attack strategies. It is also absolute to fathom the cost-efficient antiviral remedies earliest possible. METHODS: We propose to use a lab-grown organ (re-cellularized scaffold of sheep kidney) for viral culture and understand its interaction with extra-cellular matrices of the host tissue. RESULTS: Our findings showed that the chikungunya virus (CHIKV) could be better replicated in tissue-engineered bio models than cell culture. A

Antibody-Based Immunotherapeutic Strategies for the Treatment of Hematological Malignancies.

As the most common type of cancer in the world, hematological malignancies (HM) account for 10% of all annual cancer deaths and have attracted more attention. Conventional treatments, such as chemotherapy, radiotherapy, and hematopoietic stem cell transplantation (HSCT), could relieve patients suffering HM. However, serious side effects and high costs bring patients both physical complaints and mental pressure. Recently, compared with conventional therapeutic strategies for HM patients, antibody-based immunotherapies, including cancer vaccines, oncolytic virus therapies, monoclonal antibody tr

Совпадение в полном тексте источника
… This fusion protein toxin functions by cutting off the combination between DT (DAB389) and IL-2 protein, for targeting CD25 subunits of IL-2 receptors [ 42 ]; however, it is always accompanied with asthenia, fever, nausea, mild hypotension, flu-like symptoms, myalgias, chills, and vomiting [ 43 ]. … Peripheral sensory neuropathy, neutropenia, fatigue, nausea, diarrhea, fever, upper respiratory infection, vomiting Daratumumab | MM | Nasal congestion, cough, allergic rhinitis, throat irritation, dyspnea Denileukin diftitox | CTCL | Asthenia, fever, nausea, mild hypotension, flu-like symptoms, myalgias, chills …

Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion.

Patients with multiple myeloma (MM) are typically of an advanced age and may have significant co-existing medical conditions. They have often had multiple lines of therapy and as such experience disease-related effects alongside associated treatment toxicities. Daratumumab is a monoclonal antibody approved for the treatment of MM in the relapsed/refractory setting. Clinical studies found that daratumumab showed good tolerability as a monotherapy and in combination with current standard therapies. However, the administration of daratumumab does require specific management considerations. It is

Совпадение в полном тексте источника
… interruption of infusion); recurrence of symptoms following initial improvement; hospitalization indicated for other clinical sequelae 4 | Life-threatening consequences; urgent intervention indicated 5 | Death Daratumumab IRRs are characterized by nasal congestion, throat irritation, cough, as well as chills … myeloma patients treated with daratumumab monotherapy (16 mg/kg)[ 22 ] *No Grade 4, † Pneumonia also includes the terms pneumonia streptococcal and lobar pneumonia, ‡ Infusion-related reactions include, but are not limited to, the following multiple adverse reaction terms: Nasal congestion, cough, chills …

Acceptability and usefulness of the EORTC 'Write In three Symptoms/Problems' (WISP): a brief open-ended instrument for symptom assessment in cancer patients.

BackgroundThe use of open-ended questions supplementing static questionnaires with closed questions may facilitate the recognition of symptoms and toxicities. The open-ended 'Write In three Symptoms/Problems (WISP)' instrument permits patients to report additional symptoms/problems not covered by selected EORTC questionnaires. We evaluated the acceptability and usefulness of WISP with cancer patients receiving active and palliative care/treatment in Austria, Chile, France, Jordan, the Netherlands, Norway, Spain and the United Kingdom.MethodsWe conducted a literature search on validated instrum

Совпадение в полном тексте источника
… 4 | 2.5 | 1 | 1.3 | 3 | 3.7 Economic problems a | 4 | 2.5 | 2 | 2.5 | 2 | 2.5 Confusion | 3 | 1.9 | 1 | 1.3 | 2 | 2.5 Sleeping difficulties | 3 | 1.9 | 1 | 1.3 | 2 | 2.5 Cough | 3 | 1.9 | 1 | 1.3 | 2 | 2.5 Speaking problems | 3 | 1.9 | 1 | 1.3 | 2 | 2.5 Vision problems | 3 | 1.9 | 1 | 1.3 | 2 | 2.5 Chills … | 75.0 | 1 | 25.0 Confusion | 3 | 1.0 | 2 | 66.7 | 1 | 33.3 | 0 | 0.0 Sleeping difficulties | 3 | 1.0 | 1 | 33.3 | 1 | 33.3 | 1 | 33.3 Cough | 3 | 1.0 | 1 | 33.3 | 2 | 66.7 | 0 | 0.0 Speaking problems | 3 | 1.0 | 0 | 0.0 | 0 | 0.0 | 3 | 100 Vision problems | 3 | 1.0 | 1 | 33.3 | 2 | 66.7 | 0 | 0.0 Chills …

A case of hypercalcemia with double pathology.

Hypercalcemia has many causes including primary hyperparathyroidism, malignancy, and other rare etiologies. In most of the cases, hypercalcemia is secondary to one etiology. In this case, we are reporting hypercalcemia with two causes. The initial workup showed primary hyperparathyroidism due to parathyroid adenoma. But because all features were not fully explained by primary hyperparathyroidism, further work-up revealed multiple myeloma. This case represents coexistence of two different diseases, which was rarely reported in the literature previously. Usually, the co-diagnosis was made subseq

Совпадение в полном тексте источника
… She did not have abdominal pain, diarrhea, fever or chills. She reported unintentional weight loss of 50 pounds in the last seven months. The patient denied constipation, polyuria, polydipsia, bone pain, or change in mental status. No significant previous medical history was reported. …

Cancer Immunotherapies: What the Perioperative Physician Needs to Know.

Purpose of reviewFor patients with cancer, treatment may include combination therapy, including surgery and immunotherapy. Here, we review perioperative considerations for the patient prescribed immunotherapeutic agents.Recent findingsThe perioperative period is a poignant moment in the journey of a patient with cancer, potentially deemed most influential compared to other moments in the care continuum. Several immunotherapeutic medications have been employed near the time of surgery to potentially increase effectiveness. Of the various drug classes, including immune checkpoint inhibitors, cyt

Совпадение в полном тексте источника
… General symptoms of ICI toxicity included fevers, chills, and lethargy [ 16 ]. Dermatologic toxicities were usually maculopapular in nature [ 16 ]. Gastrointestinal distress was most commonly diarrhea and colitis, with or without ulceration. Hepatotoxicity manifested as elevated transaminases. … The most common adverse effects reported are chills, fatigue, fever, back pain, nausea, joint ache, and headache[ 116 ]. No studies of drug interaction have been performed with Sipuleucel-T. Acute infusion reactions are possible. …